Lee's Pharmaceutical Holdings Limited provided group earnings guidance for the six months ended 30 June 2022. For the six months, Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 25 million and HKD 30 million for the six months ended 30 June 2022 as compared with approximately HK$2.16 billion recorded for the six months ended 30 June 2021. Based on information currently available, the Board is of the view that the decrease in the profit attributable to the Shareholders of the Company for the six months ended 30 June 2022 is mainly attributable to the net effect of, among other things: the absence of one-off gain of approximately HKD 2.32 billion attributable to the derecognition of the investment in Zhaoke Ophthalmology Limited as an associate of the Company in April 2021; the absence of
an aggregate one-time loss of approximately HKD 190.1 million attributable to the estimated impairment of intangible assets due to the optimisation of R&D portfolio in the second- quarter 2021; the absence of one-time loss of approximately HKD 40.2 million attributable to the estimated impairment of an intangible asset, being the licensing fee and development cost previously capitalised, in the second-quarter 2021; and higher selling and distribution expenses incurred in the first half of 2022 to support the works for strengthening the distribution channels and preparing for the roll-out of new products.